News
Replimune (NASDAQ:REPL) stock surges as Cantor Fitzgerald upgrades, citing improved odds for approval of its lead drug after an FDA leadership change. Read more here.
Replimune (NASDAQ:REPL), and Capricor Therapeutics (NASDAQ:CAPR), which faced regulatory setbacks from the FDA’s biologics ...
The lawsuit comes after Replimune investors witnessed a 77% collapse in the price of their shares on July 22 when the company announced that the Food and Drug Administration (FDA) had rejected its ...
Asianet Newsable on MSN2d
Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes 'Major Obstacle' For Skin Cancer Drug's Potential Approval
Analysts believe the resignation of a top FDA official could lead to a reversal of the melanoma drug rejection, which was ...
The SPDR® S&P Biotech ETF rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a ...
Meta reported second-quarter revenue of $47.52 billion, beating analyst estimates of $44.58 billion, according to Benzinga ...
Should Chelsea sell the 24-year-old?...read full article ...
Artificial Intelligence has now entered retail trading with publicly available AI tools. Traders can use AI tools to save time, repl ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback